Myomo (MYO) Cash from Operations Growth (5y) (2021 - 2025)

Myomo (MYO) Cash from Operations Growth (5y) (2021 - 2025) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 182.32 Bn 175.02 Bn 6.27 Bn
2 Stryker 128.75 Bn 125.88 Bn 3.81 Bn
3 Medtronic 107.83 Bn 98.61 Bn 6.41 Bn
4 Boston Scientific 67.61 Bn 66.15 Bn 3.61 Bn
5 Edwards Lifesciences 48.13 Bn 44.45 Bn 1.29 Bn
6 Dexcom 28.26 Bn 27.14 Bn 750.30 Mn
7 GE HealthCare Technologies 27.78 Bn 25.50 Bn 1.98 Bn
8 Smith & Nephew 26.99 Bn 26.41 Bn -
9 Koninklijke Philips 23.92 Bn 20.80 Bn 2.07 Bn
10 Myomo 43.43 Mn 24.46 Mn -

Historic Data

Download Data
DateValue
Sep 30, 2025 -0.32%
Jun 30, 2025 -19.39%
Mar 31, 2025 -1.83%
Dec 31, 2024 26.76%
Sep 30, 2024 8.19%
Jun 30, 2024 3.48%
Mar 31, 2024 -0.79%
Dec 31, 2023 1.28%
Sep 30, 2023 7.14%
Jun 30, 2023 34.37%
Mar 31, 2023 4.32%
Dec 31, 2022 -9.83%
Sep 30, 2022 -8.47%
Jun 30, 2022 -10.81%
Mar 31, 2022 -14.86%
Dec 31, 2021 -15.37%
Sep 30, 2021 -10.76%